BioCryst Pharmaceuticals | BCRX - Net Income


BioCryst Pharmaceuticals reported $-88.88M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
BioCryst Pharmaceuticals USD -88.88M 74.85M Dec/2024
Chugai Pharma JPY 128.41B 17.2B Dec/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Glaxosmithkline GBP 2.71B 1.27B Sep/2025
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novavax USD -121.3M 283.68M Sep/2024
PTC Therapeutics USD 15.9M 80.75M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025